Medtronic Launches aDBS System in India
Analysis based on 6 articles · First reported Apr 22, 2026 · Last updated Apr 27, 2026
The launch of Medtronic's aDBS system in India is expected to positively impact Medtronic's market position in the healthcare technology sector, particularly in the growing market of India. It addresses a significant public health concern, potentially leading to increased revenue and market share for Medtronic.
Medtronic, a global healthcare technology leader, launched its Adaptive Deep Brain Stimulation (aDBS) system in India on April 27, 2026. This innovative system, which uses BrainSense technology approved by the United States — Food and Drug Administration, is designed to automatically adjust therapy for patients with Parkinson's disease, offering more consistent symptom management and minimizing side effects. The introduction of aDBS comes at a critical time as India is projected to become the second-highest country globally for Parkinson's disease cases within the next five years. Prateek Tiwari of Medtronic India emphasized the company's commitment to improving patients' quality of life and strengthening its leadership in bringing cutting-edge healthcare technologies to India.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard